Précédent|Prochain

Analyse des modèles animaux de diminution de la réserve ovarienne basés sur les caractéristiques cliniques des syndromes chinois et occidentaux

  • role： First author第一作者
  • Affiliation：

    Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China

  • Email：1481034625@qq.com
  • Introduction：于明玥，在读博士，从事卵巢储备功能减退疾病的相关研究，E-mail：1481034625@qq.com
YU Mingyue,  
  • role： Corresponding author通信作者
  • Affiliation：

    Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China

  • Email：tangling73@126.com
  • Introduction：汤玲，博士，主任医师，博士生导师，从事中医药防治妇科疾病相关研究，Tel：010-84013040，E-mail：tangling73@126.com
TANG Ling*,  
  • Affiliation：

    Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China

SUN Xiaohui,  
  • Affiliation：

    Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China

ZHAO Jingjing

résumé

Avec le développement de la société et l'augmentation de la demande des femmes pour une grossesse à âge avancé, l'insuffisance de la réserve ovarienne (DOR) attire une attention croissante. Cette maladie affecte non seulement le cycle menstruel normal des femmes, mais menace également leur santé mentale. Actuellement, la recherche sur la DOR en est encore à ses débuts, et la construction d'un modèle animal efficace et réaliste est une nécessité pour faire progresser les recherches sur la DOR. Cette étude vise à utiliser les documents existants en combinaison avec les critères de diagnostic de la médecine chinoise et occidentale pour résumer, analyser et évaluer les modèles existants, fournissant ainsi une référence pour optimiser les modèles animaux de la DOR. Méthode: analyse rétrospective de la littérature sur les modèles animaux liés à la DOR, classement des critères de diagnostic chinois et occidental, évaluation du degré de correspondance clinique entre médecine chinoise et occidentale selon les méthodes d'évaluation des modèles animaux. Résultats: les modèles animaux de DOR comprennent des modèles liés à des facteurs naturels, médicaux, immunitaires, métaboliques et environnementaux. Parmi eux, le modèle médical, en particulier les modèles induits par des préparations de Tripterygium wilfordii, le cyclophosphamide et le cisplatine, présente un haut niveau de correspondance tant dans les maladies occidentales que dans les types de syndrome chinois, étant la meilleure méthode de modélisation DOR actuellement. Conclusion: la plupart des méthodes de modélisation actuelles de la DOR ont une forte correspondance clinique avec les maladies occidentales, mais il existe peu de modèles animaux DOR avec des syndromes chinois clairement définis. Sur la voie de l'exploration des traitements DOR, le rôle de la médecine chinoise ne peut être ignoré. Il est donc nécessaire de développer activement des modèles animaux DOR liés aux syndromes chinois afin de mieux exploiter le potentiel de la médecine chinoise et de fournir un soutien théorique solide pour l'application de la médecine chinoise dans le traitement de la DOR.

mots-clés

diminution de la réserve ovarienne;modèles animaux;combinaison syndrome-maladie

References

  1. 1.
    WANG Y，LV C，HUANG H L，et al.Influence of mouse defective zona pellucida in folliculogenesis on apoptosis of granulosa cells and developmental competence of oocytes［J］.Biol Reprod，2019，101（2）：457-465.
  2. 2.
    Expert Group of Consensus on Clinical Diagnosis & Management of Diminished Ovarian Reserve，Reproductive Endocrinology & Fertility Preservation Section of Chinese Society on Fertility Preservation under Chinese Preventive Medicine Association.Consensus on the clinical diagnosis and management of diminished ovarian reserve［J］.J Reproduct Med，2022，31（4）：425-434.
  3. 3.
    ZHANG Q L，LEI Y L，DENG Y，et al.Treatment progress in diminished ovarian reserve：Western and Chinese medicine［J］.Chin J Integr Med，2023，29（4）：361-367.
  4. 4.
    JIN X，WANG K，WANG L，et al.RAB7 activity is required for the regulation of mitophagy in oocyte meiosis and oocyte quality control during ovarian aging［J］.Autophagy，2022，18（3）：643-660.
  5. 5.
    ZHANG T，HE M，ZHANG J，et al.Mechanisms of primordial follicle activation and new pregnancy opportunity for premature ovarian failure patients［J］.Front Physiol，2023，14：1113684.
  6. 6.
    ZHANG H，PANULA S，PETROPOULOS S，et al.Adult human and mouse ovaries lack DDX4-expressing functional oogonial stem cells［J］.Nat Med，2015，21（10）：1116-1118.
  7. 7.
    CHE Q，DONG X.Progress in the diagnosis and treatment of low ovarian reserve function［J］.J Practical Obstetrics Gynecol，2024，40（7）：517-519.
  8. 8.
    LI F，ZHU J，LIU J，et al.Targeting estrogen receptor beta ameliorates diminished ovarian reserve via suppression of the FOXO3a/autophagy pathway［J］.Aging Dis，2025，16（1）：479-497.
  9. 9.
    XIAO X.Clinical study and mechanism of ovarian reserve hypoplasia intervened by beneficial kidney and liver sharing soup［D］.Beijing：Beijing University of Traditional Chinese Medicine，2023.
  10. 10.
    WANG C M，TANG L，XIAO C C.XIAO Chengcong's experience in treating ovarian reserve function with benefiting the kidney and regulating thoroughfare channel method［J］.J Tradit Chin Med，2019，60（14）：1188-1190.
  11. 11.
    LV X L，GAO J，ZHOU Y X，et al.LUO Songping's experience in treating infertility due to decreased ovarian reserve function［J］.J Tradit Chin Med，2020，61（13）：1139-1141.
  12. 12.
    YANG Q，YANG W W，CAI L X，et al.Clinical effect of CAI's Bushen Tianjing formula on diminished ovarian reserve due to liver-kidney Yin deficiency［J］.World Chin Med，2023，18（24）：3561-3566.
  13. 13.
    Practice Committee of the American Society for Reproductive Medicine.Testing and interpreting measures of ovarian reserve：A committee opinion［J］.Fertil Steril，2020，114（6）：1151-1157.
  14. 14.
    TIAN S，CAO L H，MIAO M S，et al.A new method for the evaluation of animal models used in traditional Chinese medicine based onthe clinical characteristics of Chinese and Western medicine［J］.Pharmacol Clin Chin Mater Med，2017，33（6）：165-169.
  15. 15.
    Chinese Society of Traditional Chinese Medicine.Guidelines for the diagnosis and treatment of common diseases in Chinese medicine and gynecology［M］.Beijing：China Press of Traditional Chinese Medicine，2012.
  16. 16.
    XIN X Y，YE Y，FAN R W，et al.Diagnosis and treatment plan of integrated Chinese and western medicine for infertility（decreased ovarian reserve function）［J］.Beijing J Tradit Chin Med，2024，43（2）：119-123.
  17. 17.
    TAN Y.Chinese medicine gynecology［M］.4 ed.Beijing：China Press of Traditional Chinese Medicine，2016：152-161.
  18. 18.
    SUN X H.Analysis of the correlation between Chinese medicine evidence of ovarian reserve hypoplasia and body mass distribution and pentamorphic personality［D］.Beijing：Beijing University of Chinese Medicine，2023.
  19. 19.
    LIU L Q，LIU Y F，WANG Y Z，et al.Characteristics of TCM syndromes and medication rules in treatment of diminished ovarian reserve based on data mining［J］.Chin J Inf Tradit Chin Med，2021，28（6）：33-38.
  20. 20.
    MA W W，XU L W.Distribution of Chinese medical syndromes of diminished ovarian reserve［J］.Clin J Tradit Chin Med，2018，30（6）：1068-1071.
  21. 21.
    DAI J F.Development of TCM syndrome and diagnosis scalefor decreased ovarian reserve function［D］.Nanchang：Jiangxi University of Chinese Medicine，2023.
  22. 22.
    XU X F，TAN Y，CHEN X Y.The advantages of traditional Chinese medicine in the treatment of ovarian reserve decline［J］.Chin J Inf TCM，2009，16（12）：88-89.
  23. 23.
    DAI J F，SHENG M Z，YU K，et al.A study on the screening of entries in the diagnostic scale for ovarian reserve hypoplasia in Chinese medicine［J］.J Chin Med，2025，doi：.
  24. 24.
    JIN Z，BU X L.Traditional Chinese medicine strategies for assisting pregnancy in ovarian reserve function decline［J］.J Practical Obstetrics Gynecol，2021，37（10）：729-731.
  25. 25.
    YAN D W，ZHOU L，SUN Z Y.Reserch progress in establishing animal models of prematureovarian failure and its evaluation indexes［J］.Chin J Pharmacol Toxicol，2015，29（3）：486-492.
  26. 26.
    LIU H，JIANG C，LA B，et al. Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through AMPK/FoxO3a signaling pathway［J］.Stem Cell Res Ther，2021，12（1）：317.
  27. 27.
    YAN R G，QI F H，HE J，et al.Effect of Yishen Tiaojing prescription on PTEN/PI3K/Akt signaling pathway in ovarian tissueof rats with decreased ovarian reserve［J］.J Chin Med Mater，2022，45（7）：1714-1720.
  28. 28.
    LI Y H.Study on the efficacy and mechanism of kidney tonifying and liver-sparing formula combined with five elements of music to intervene in ovarian reserve hypoplasia［D］.Beijing：Beijing University of Chinese Medicine，2021.
  29. 29.
    DENG D S，YAN J，LI W J，et al.Protective effect of Xinjia Congrong Tusizi Wan on the reproductive toxicity of female rats induced by triptolide［J］.Evid Based Complement Alternat Med，2022，2022：3642349.
  30. 30.
    ZHOU F，ZENG J，WANG Y L，et al.The mechanism of Bushen Jianpi formula regulating diminished ovarianreserve in rats based on related apoptosis pathways［J］.J Hunan Univ Chin Med，2024，44（7）：1167-1174.
  31. 31.
    ZHANG L L.Clinical efficacy and mechanism study of Qianyang Fengsui pills in treating diminished ovarian reserve（deficiency syndrome ofboth kidney Yin and Yang）［D］.Changchun：Changchun University of Chinese Medicine，2024.
  32. 32.
    ZHANG S，ZHOU H F，LIU Y N，et al.Modified Dihuang decoction improves ovarian reserve in mice byregulating Bcl-2-related mitochondrial apoptosis pathway［J］.China J Chin Mater Med，2021，46（24）：6493-6501.
  33. 33.
    CUI N.Clinical and mechanism study on the improving diminished ovarian reserve by Bushen Tianjing Chinese medicine［D］.Beijing：China Academy of Chinese Medical Sciences，2023.
  34. 34.
    HAN F F.Clinical and experimental study on the effect of kidney tonifying and essence filling decoction on bone metabolism related to diminished ovarian reserve［D］.Beijing：China Academy of Chinese Medical Sciences，2023.
  35. 35.
    CUI D D，MA W W，WEN L，et al.Effect of Guishen pill on expression levels of Oct-4、MVH and Egr-1 in mice with diminished ovarian reserve［J］.Chin J Integrated Tradit Western Med，2015，35（1）：76-80.
  36. 36.
    LAO J，HU P，LI J，et al.Acupuncture combined with Bushen-Jianpi decoction ameliorates the ovarian function of diminished ovarian reserve rats by regulating phosphoinositide 3-kinase/Akt signaling［J］.Comb Chem High Throughput Screen，2024，27（16）：2402-2418.
  37. 37.
    FENG G L，LI J，ZHOU X L.Effect of Bushen Jianpi Fang on sex hormone and oocyte quality in mice with immune ovarian function decline［J］.J Tradit Chin Med，2016，57（16）：1416-1420.
  38. 38.
    JIANG S S，WANG Y J，PANG X Y，et al.Effects of Angelica sinensis and Paeonia lactiflora on PI3K/Akt/FoxO3a signaling pathway in mice with decreased ovarian reserve function［J］.Lishizhen Med Mater Med Res，2021，32（6）：1335-1338.
  39. 39.
    WANG Y X，LI Z A，ZHENG Y L，et al.Exploring effect of Buchong Tiaojing prescription on iron death in ovarian tissues of ratswith diminished ovarian reserve model based on NLRP3 inflammasome［J］.Chin J Exp Tradit Med Form，2025，31（3）：40-48.
  40. 40.
    ZHANG L R，YAN H C.Effect of red ginseng on improving ovarian reserve function and PI3K/Akt/mTOR signaling pathway in ovarian tissue of rats with decreased ovarian reserve［J］.Anhui Med Pharmaceut J，2024，28（7）：1323-1327，1487.
  41. 41.
    LEE H J，PARK M J，JOO B S，et al. Effects of coenzyme Q10 on ovarian surface epithelium-derived ovarian stem cells and ovarian function in a 4-vinylcyclohexene diepoxide-induced murine model of ovarian failure［J］. Reprod Biol Endocrinol，2021，19（1）：59.
  42. 42.
    YU S D，HE X，SHI H Y，et al.Effects of electroacupuncture on ovarian reserve function of ovarian injury rats at different time-point［J］.J Basic Chin Med，2022，28（8）：1254-1258.
  43. 43.
    KOLE E，OZKAN S O，ERALDEMIR C，et al.Effects of melatonin on ovarian reserve in cigarette smoking： an experimental study［J］.Arch Med Sci，2020，16（6）：1376-1386.
  44. 44.
    GAO L，ZHAO F，ZHANG Y，et al.Diminished ovarian reserve induced by chronic unpredictable stress in C57BL/6 mice［J］.Gynecol Endocrinol，2020，36（1）：49-54.
  45. 45.
    LIU X Y，QI A R，LUO D G，et al.Research progress in reproductive toxicity and detoxification by combined use of Tripterygium wilfordill Hook［J］.Chin J Inf TCM，2018，25（4）：133-135.
  46. 46.
    LIU T E，ZHANG L，WANG S，et al.Tripterygium glycosides induce premature ovarian failure in rats by promoting p53 phosphorylation and activating the serine/threonine kinase 11-p53-p21 signaling pathway［J］.Exp Ther Med，2015，10（1）：12-18.
  47. 47.
    GU R Y，HE L，ZHANG Q M，et al.Regulatory effect of the prescription for nourishing Yin and warming Yang in a sequential wayon the animal model of ovarianon the animal model of ovaria［J］.Jilin J Chin Med，2022，42（10）：1189-1194.
  48. 48.
    CHENG Q，DING Y，HUANG X，et al.Analysis of establishing animal model of ovarian dysfunction with Tripterygium wilfordii preparation based on literature mining［J］.Tradit Chin Drug Res Clin Pharmacol，2024，35（4）：547-552.
  49. 49.
    ZHAO Y T，YIN H，HU C，et al.Tilapia skin peptides restore cyclophosphamide-induced premature ovarian failure via inhibiting oxidative stress and apoptosis in mice［J］.Food Funct，2022，13（3）：1668-1679.
  50. 50.
    XIE Q.Exploration of mechanisms of cyclophosphamide-induced diminished ovarian reserve［D］.Wuhan：Huazhong University of Science and Technology，2022.
  51. 51.
    MO J H，HU H，YAN Q X，et al.A comparative study of cyclophosphamide witn different doses and withdrawal cycles in constructing animal model of premature ovarian failure in mice［J］.J Reprod Med，2024，33（3）：365-372.
  52. 52.
    SPEARS N，LOPES F，STEFANSDOTTIR A，et al.Ovarian damage from chemotherapy and current approaches to its protection［J］.Hum Reprod Update，2019，25（6）：673-693.
  53. 53.
    AI H.Research on pathomechanism of premature ovarian failure induced by chemotherapy and regulation effect of genestin on premature ovarian failure［D］.Beijing：Beijing University of Chinese Medicine，2007.
  54. 54.
    LI W X，DU P F，ZHU Y Y，et al.Dosage of 4-vinylcyclohexene diepoxide in induction of premature ovarian insufficiency in rats［J］.Chin J Exp Tradit Med Form，2024，30（18）：72-79.
  55. 55.
    VAN KEMPEN T A，MILNER T A，WATERS E M.Accelerated ovarian failure：A novel，chemically induced animal model of menopause［J］.Brain Res，2011，1379：176-187.
  56. 56.
    LI F，WANG Y，XU M，et al.Single-nucleus RNA Sequencing reveals the mechanism of cigarette smoke exposure on diminished ovarian reserve in mice［J］.Ecotoxicol Environ Saf，2022，245：114093.
  57. 57.
    WEI D R.A Meta-analysis of traditional Chinese medicine compound treatment of POI based on simultaneous treatment of the iiver and kidney and an experimental study of Zishen Ankun granules on immune POI mice［D］.Chengdu： Chengdu University of Traditional Chinese Medicine，2023.
  58. 58.
    ALEJANDRO S P.ER stress in cardiac aging，a current view on the D-galactose model［J］.Exp Gerontol，2022，169：111953.
  59. 59.
    HE L，WANG X，CHENG D，et al.Ginsenoside Rg1 improves pathological damages by activating the&nbsp；p21‑p53‑STK pathway in ovary and Bax‑Bcl2 in the uterus in premature ovarian insufficiency mouse models［J］.Mol Med Rep，2021，23（1）：37.
  60. 60.
    LIN Y，ZHANG T，LI X，et al.Research overview of animal models with kidney deficiency sydnrome of traditional Chinese medicine［J］.Chin Arch Tradit Chin Med，2020，38（1）：136-139.
  61. 61.
    DAI B，ZHANG J N，YANG M L，et al.Establishment of a mouse model of kidney deficiency induced by oraladministration of hydrocortisone and evaluation of related factors［J］.Acta Lab Animalis Sci Sin，2017，25（1）：70-73.
  62. 62.
    ZHEN Y H，LI K Y，HUANG J M，et al.Research progress on establishment methods of animal models of liver stagnation and spleen deficiency syndrome［J］.Chin Arch Tradit Chin Med，2020，38（9）：121-124.
  63. 63.
    LIU Y，ZHANG Q X，CHANG X，et al.Establishment and Thinking of Rat model of asthma combined withpathological syndrome of cold fluid retention in lung［J］.Chin Arch Tradit Chin Med，2019，37（3）：586-588，777.
  64. 64.
    LU C，LIN L，TAN H，et al. Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice［J］. Hum Mol Genet，2012，21（23）：5039-5047.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website